GlaxoSmithKline finally got some good news from a study of its diabetes drug Avandia, but some top leading cardiologists remain unconvinced, saying the company’s new research has serious flaws.
The results, unveiled late this afternoon at the American Diabetes Association conference in New Orleans, found Avandia doesn’t increase patients’ risk for heart attacks, according [...]